Natera, Inc. (NASDAQ:NTRA) Shares Sold by Brown Capital Management LLC

Brown Capital Management LLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 73.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,894 shares of the medical research company's stock after selling 7,940 shares during the period. Brown Capital Management LLC's holdings in Natera were worth $367,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new position in Natera during the second quarter worth approximately $28,000. Quarry LP boosted its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. GAMMA Investing LLC increased its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock valued at $35,000 after buying an additional 108 shares during the last quarter. Covestor Ltd lifted its stake in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after purchasing an additional 95 shares during the last quarter. Finally, Tobam bought a new stake in shares of Natera during the 2nd quarter valued at about $74,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

Shares of NTRA stock traded up $1.32 during trading hours on Thursday, reaching $169.20. The company had a trading volume of 1,106,627 shares, compared to its average volume of 1,346,857. The firm has a market cap of $22.34 billion, a PE ratio of -96.23 and a beta of 1.53. Natera, Inc. has a one year low of $53.62 and a one year high of $171.95. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The business has a fifty day moving average price of $129.84 and a 200-day moving average price of $117.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.95) EPS. Sell-side analysts predict that Natera, Inc. will post -1.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on NTRA. StockNews.com cut Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. Piper Sandler raised their price target on shares of Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a report on Monday. BTIG Research lifted their target price on shares of Natera from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Craig Hallum boosted their target price on shares of Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Stephens reissued an "overweight" rating and issued a $125.00 price target on shares of Natera in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $140.59.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the firm's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares of the company's stock, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of the business's stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the transaction, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,821 shares of company stock valued at $4,776,878 in the last ninety days. Insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.